ABUS vs ROK · P/E 5.4, rev $6.2M vs P/E 48, rev $8.34B
Arbutus Biopharma Corp (ABUS) versus Rockwell Automation Inc (ROK) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Rockwell Automation Inc (ROK) is a specialty industrial machinery company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported ROK revenue for 2025-09-30 was $8.34B. Net income was $749.0M. Revenue was up 0.9% from 2024-09-30 to 2025-09-30. ROK currently screens at market cap $51.04B and trailing P/E 47.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. ROK currently screens at market cap $51.04B and trailing P/E 47.5.
Not investment advice. Open the ABUS and ROK stock pages for the full models.
Not investment advice.